THE ELITE
TEST BANK:
UT AUSTIN
DNP
MASTER'S
BLUEPRINT
2026/2027
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Panic Button" Cheat Sheet
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Questions 1–15)
■ Focus: GOLD 2026 'ABE' Criteria, ADA 2026 Technology Standards, AHA
, PREVENT 2026 Equation, MASLD Nomenclature, Texas AI Disclosure Laws
(SB 1188).
○ Section 2: Professional Simulation (Questions 16–40)
■ Focus: Acute Exacerbation Protocols, Euglycemic DKA, Sepsis-3 (1-Hour
Bundle vs. qSOFA), AHA Dyslipidemia Targets, CPR Redline Updates.
○ Section 3: Grandmaster Synthesis (Questions 41–66)
■ Focus: Multi-System Failure, Joint Commission NPG 12 Compliance, UT
Austin NRP 395L Quality Improvement, Practice-Based Evidence (PBE).
PART I: THE PRIMER
Mastering the 2026/2027 clinical and regulatory updates transcends academic achievement; it
is the definitive requirement for averting systemic patient harm and maintaining institutional
accreditation in high-stakes environments. Advanced practice leadership demands the
replacement of outdated legacy algorithms with razor-sharp, data-driven professional intuition.
The "Panic Button" Cheat Sheet
● GOLD 2026 'ABE' Escalation: A single moderate COPD exacerbation instantly
reclassifies the patient to Group E, mandating immediate LAMA/LABA dual therapy.
● AHA PREVENT 2026 Equation: Replaces legacy pooled cohort equations; estimates
combined ASCVD and Heart Failure risk, eliminates race variables, and integrates the
Social Deprivation Index (SDI) and eGFR.
● ADA 2026 Technology Standard: Automated Insulin Delivery (AID) is the absolute
preferred standard for all Type 1 and insulin-dependent Type 2 diabetes; "step-therapy" is
obsolete.
● JCAHO NPG 12 (2026): Mandates a designated Nurse Executive to oversee 24/7 staffing
driven strictly by patient acuity and validated staff competencies.
● Texas SB 1188 / HB 149: Mandates explicit, plain-language patient disclosure for all
AI-assisted diagnostic tools and strictly prohibits the offshoring of EHRs.
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application
Q1: A 64-year-old client with chronic obstructive pulmonary disease (COPD) presents to the
clinic for a routine evaluation. The electronic health record indicates the client experienced
exactly one moderate exacerbation in the past 11 months, which was managed with oral
corticosteroids without requiring hospitalization. Based on the 2026 GOLD Report, what is the
MOST APPROPRIATE INITIAL classification and pharmacological approach? A) Classify as
Group A; initiate short-acting bronchodilator therapy. B) Classify as Group B; initiate long-acting
muscarinic antagonist (LAMA) monotherapy. C) Classify as Group E; initiate LAMA/LABA dual
bronchodilation therapy. D) Classify as Group C; initiate inhaled corticosteroid (ICS)
monotherapy.
● The Answer: C (Classify as Group E; initiate LAMA/LABA dual bronchodilation therapy.)
● Distractor Analysis:
○ A & B are incorrect: Legacy guidelines required two exacerbations to escalate risk.
The 2026 update dictates that a single moderate exacerbation elevates the patient
immediately out of low-risk categories.
, ○ D is incorrect: Group C is obsolete in the 2026 ABE framework, and ICS
monotherapy is strictly contraindicated in COPD due to pneumonia risk.
The Mentor's Analysis: The GOLD 2026 paradigm shift eliminates the dangerous
"wait-and-see" approach. A single exacerbation is no longer considered a random clinical flare;
it is a definitive, permanent marker of an exacerbation-prone phenotype.
Metric Legacy GOLD (ABCD) 2026 GOLD (ABE)
High Risk Trigger \ge 2 moderate exacerbations \ge 1 moderate exacerbation
Initial High-Risk Tx LAMA monotherapy LABA + LAMA dual therapy
Professional Intuition: Treat the first exacerbation as a critical systemic failure requiring
immediate dual-pathway blockade to prevent irreversible lung tissue destruction.
Q2: During a routine metabolic evaluation, a client with Type 1 diabetes expresses profound
frustration with multiple daily injections (MDI). Under the ADA 2026 Standards of Care, which
action represents the BEST evidence-based intervention by the advanced practitioner? A)
Require a 6-month trial of continuous glucose monitoring (CGM) alone before transitioning off
MDI. B) Immediately transition the client to an Automated Insulin Delivery (AID) system. C)
Step-up therapy to a standard continuous subcutaneous insulin infusion (CSII) pump without
hybrid closed-loop automation. D) Prescribe a sliding scale regimen to provide the client with
more autonomy over injection timing.
● The Answer: B (Immediately transition the client to an Automated Insulin Delivery (AID)
system.)
● Distractor Analysis:
○ A & C are incorrect: The 2026 ADA guidelines dismantle the "stepping stone"
approach. AID is the preferred, first-line delivery system, superior to MDI and basic
CSII for all T1D patients.
○ D is incorrect: Sliding scale regimens are highly reactive, outdated, and rapidly
increase the risk of severe glycemic excursions and diabetic ketoacidosis.
The Mentor's Analysis: The 2026 standard treats advanced hybrid closed-loop technology as
baseline care, not a luxury reserved for those who "fail" basic therapy. Professional Intuition:
Withholding automated technology from an insulin-dependent patient is akin to withholding
telemetry from a critically ill cardiac patient. Provide the technology upfront.
Q3: A practitioner is utilizing the 2026 AHA PREVENT Calculator for a 45-year-old client
undergoing primary prevention screening. Which physiological variable is NEWLY REQUIRED
by this specific tool to accurately estimate the 10-year risk for total cardiovascular disease? A)
Patient race and ethnicity. B) Fasting serum triglyceride levels. C) Estimated Glomerular
Filtration Rate (eGFR). D) High-sensitivity C-reactive protein (hs-CRP).
● The Answer: C (Estimated Glomerular Filtration Rate (eGFR).)
● Distractor Analysis:
○ A is incorrect: The PREVENT equation explicitly removes race from its algorithm to
eliminate historical demographic bias and focus on actual physiology.
○ B & D are incorrect: While useful clinically, they are not the defining new baseline
variables integrated into the core PREVENT mathematical tool.
○ C is correct: PREVENT is the first major tool to mandate kidney health metrics
(eGFR) and metabolic factors as core predictors for ASCVD and Heart Failure.
The Mentor's Analysis: Cardiovascular, kidney, and metabolic systems are not isolated silos;
they operate as a single, interconnected hemodynamic web known as CKM syndrome.
Professional Intuition: You cannot accurately assess the vascular health of the heart without
simultaneously interrogating the filtration pressure of the kidneys. The endothelium is
, contiguous.
Q4: A client formerly diagnosed with "Nonalcoholic Fatty Liver Disease" (NAFLD) is being
re-evaluated under the updated 2025/2026 nomenclature standard. To accurately diagnose the
client with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), the practitioner
MUST definitively identify hepatic steatosis alongside which of the following? A) A history of
chronic alcohol consumption exceeding 210 g/week. B) At least one cardiometabolic risk factor,
such as hypertension, obesity, or type 2 diabetes. C) A diagnostic liver biopsy demonstrating
bridging fibrosis and hepatocyte ballooning. D) Elevated liver transaminases (AST/ALT)
exceeding three times the upper limit of normal.
● The Answer: B (At least one cardiometabolic risk factor, such as hypertension, obesity, or
type 2 diabetes.)
● Distractor Analysis:
○ A is incorrect: Heavy alcohol use reclassifies the patient into the "MetALD" category
or alcohol-related liver disease, removing them from pure MASLD.
○ C & D are incorrect: Biopsy and severe transaminase elevations denote severity
(MASH) but are not the baseline definitional requirements for the overarching
MASLD umbrella.
The Mentor's Analysis: The nomenclature shift from NAFLD to MASLD is not merely semantic;
it is a profound clinical acknowledgment that steatosis is a direct downstream consequence of
systemic metabolic dysfunction. Professional Intuition: Always treat a fatty liver as a
screaming metabolic red flag, inextricably linked to cardiovascular and diabetic risk profiles. It is
a systemic disease, not a localized hepatic anomaly.
Q5: An advanced practice nurse in Texas is utilizing a predictive AI algorithm to assist in
diagnosing a highly complex dermatological lesion. To comply with Texas Senate Bill 1188
(effective Sept 2025), what is the MANDATORY action the practitioner must execute? A) Obtain
written consent from the Texas Medical Board prior to utilizing the software on the clinic network.
B) Disclose the use of the AI diagnostic technology clearly and conspicuously to the patient. C)
Ensure the AI algorithm is hosted on a cloud server physically located in the European Union to
guarantee privacy. D) Anonymize all patient data entirely before the AI processes the diagnostic
image.
● The Answer: B (Disclose the use of the AI diagnostic technology clearly and
conspicuously to the patient.)
● Distractor Analysis:
○ A is incorrect: TMB consent per use is not required, though the practitioner must
review outputs according to standard TMB rules.
○ C is incorrect: SB 1188 strictly prohibits the physical offshoring of Electronic Health
Records (data localization mandate).
○ D is incorrect: While HIPAA privacy is paramount, explicit disclosure of the AI's role
in the care process is the specific, novel legal mandate created by this bill.
The Mentor's Analysis: AI is a powerful decision-support tool, but it does not absorb clinical or
legal liability. The law demands total transparency so patients maintain autonomy over their care
pathways. Professional Intuition: Technology supports the diagnosis, but the practitioner owns
the outcome and the ethical duty to disclose. Never hide the algorithm behind the curtain.
Q6: A hospital network is auditing its internal protocols to ensure strict compliance with the Joint
Commission's National Performance Goal 12 (NPG 12) for 2026. Which action demonstrates
STRICT COMPLIANCE with this new standard? A) Implementing a rigid, hospital-wide ratio of 1
nurse to 5 patients across all acute care units. B) Designating a licensed Nurse Executive (RN)
to oversee continuous, acuity-based staffing assessments and 24/7 RN coverage. C) Replacing
TEST BANK:
UT AUSTIN
DNP
MASTER'S
BLUEPRINT
2026/2027
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Panic Button" Cheat Sheet
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Questions 1–15)
■ Focus: GOLD 2026 'ABE' Criteria, ADA 2026 Technology Standards, AHA
, PREVENT 2026 Equation, MASLD Nomenclature, Texas AI Disclosure Laws
(SB 1188).
○ Section 2: Professional Simulation (Questions 16–40)
■ Focus: Acute Exacerbation Protocols, Euglycemic DKA, Sepsis-3 (1-Hour
Bundle vs. qSOFA), AHA Dyslipidemia Targets, CPR Redline Updates.
○ Section 3: Grandmaster Synthesis (Questions 41–66)
■ Focus: Multi-System Failure, Joint Commission NPG 12 Compliance, UT
Austin NRP 395L Quality Improvement, Practice-Based Evidence (PBE).
PART I: THE PRIMER
Mastering the 2026/2027 clinical and regulatory updates transcends academic achievement; it
is the definitive requirement for averting systemic patient harm and maintaining institutional
accreditation in high-stakes environments. Advanced practice leadership demands the
replacement of outdated legacy algorithms with razor-sharp, data-driven professional intuition.
The "Panic Button" Cheat Sheet
● GOLD 2026 'ABE' Escalation: A single moderate COPD exacerbation instantly
reclassifies the patient to Group E, mandating immediate LAMA/LABA dual therapy.
● AHA PREVENT 2026 Equation: Replaces legacy pooled cohort equations; estimates
combined ASCVD and Heart Failure risk, eliminates race variables, and integrates the
Social Deprivation Index (SDI) and eGFR.
● ADA 2026 Technology Standard: Automated Insulin Delivery (AID) is the absolute
preferred standard for all Type 1 and insulin-dependent Type 2 diabetes; "step-therapy" is
obsolete.
● JCAHO NPG 12 (2026): Mandates a designated Nurse Executive to oversee 24/7 staffing
driven strictly by patient acuity and validated staff competencies.
● Texas SB 1188 / HB 149: Mandates explicit, plain-language patient disclosure for all
AI-assisted diagnostic tools and strictly prohibits the offshoring of EHRs.
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application
Q1: A 64-year-old client with chronic obstructive pulmonary disease (COPD) presents to the
clinic for a routine evaluation. The electronic health record indicates the client experienced
exactly one moderate exacerbation in the past 11 months, which was managed with oral
corticosteroids without requiring hospitalization. Based on the 2026 GOLD Report, what is the
MOST APPROPRIATE INITIAL classification and pharmacological approach? A) Classify as
Group A; initiate short-acting bronchodilator therapy. B) Classify as Group B; initiate long-acting
muscarinic antagonist (LAMA) monotherapy. C) Classify as Group E; initiate LAMA/LABA dual
bronchodilation therapy. D) Classify as Group C; initiate inhaled corticosteroid (ICS)
monotherapy.
● The Answer: C (Classify as Group E; initiate LAMA/LABA dual bronchodilation therapy.)
● Distractor Analysis:
○ A & B are incorrect: Legacy guidelines required two exacerbations to escalate risk.
The 2026 update dictates that a single moderate exacerbation elevates the patient
immediately out of low-risk categories.
, ○ D is incorrect: Group C is obsolete in the 2026 ABE framework, and ICS
monotherapy is strictly contraindicated in COPD due to pneumonia risk.
The Mentor's Analysis: The GOLD 2026 paradigm shift eliminates the dangerous
"wait-and-see" approach. A single exacerbation is no longer considered a random clinical flare;
it is a definitive, permanent marker of an exacerbation-prone phenotype.
Metric Legacy GOLD (ABCD) 2026 GOLD (ABE)
High Risk Trigger \ge 2 moderate exacerbations \ge 1 moderate exacerbation
Initial High-Risk Tx LAMA monotherapy LABA + LAMA dual therapy
Professional Intuition: Treat the first exacerbation as a critical systemic failure requiring
immediate dual-pathway blockade to prevent irreversible lung tissue destruction.
Q2: During a routine metabolic evaluation, a client with Type 1 diabetes expresses profound
frustration with multiple daily injections (MDI). Under the ADA 2026 Standards of Care, which
action represents the BEST evidence-based intervention by the advanced practitioner? A)
Require a 6-month trial of continuous glucose monitoring (CGM) alone before transitioning off
MDI. B) Immediately transition the client to an Automated Insulin Delivery (AID) system. C)
Step-up therapy to a standard continuous subcutaneous insulin infusion (CSII) pump without
hybrid closed-loop automation. D) Prescribe a sliding scale regimen to provide the client with
more autonomy over injection timing.
● The Answer: B (Immediately transition the client to an Automated Insulin Delivery (AID)
system.)
● Distractor Analysis:
○ A & C are incorrect: The 2026 ADA guidelines dismantle the "stepping stone"
approach. AID is the preferred, first-line delivery system, superior to MDI and basic
CSII for all T1D patients.
○ D is incorrect: Sliding scale regimens are highly reactive, outdated, and rapidly
increase the risk of severe glycemic excursions and diabetic ketoacidosis.
The Mentor's Analysis: The 2026 standard treats advanced hybrid closed-loop technology as
baseline care, not a luxury reserved for those who "fail" basic therapy. Professional Intuition:
Withholding automated technology from an insulin-dependent patient is akin to withholding
telemetry from a critically ill cardiac patient. Provide the technology upfront.
Q3: A practitioner is utilizing the 2026 AHA PREVENT Calculator for a 45-year-old client
undergoing primary prevention screening. Which physiological variable is NEWLY REQUIRED
by this specific tool to accurately estimate the 10-year risk for total cardiovascular disease? A)
Patient race and ethnicity. B) Fasting serum triglyceride levels. C) Estimated Glomerular
Filtration Rate (eGFR). D) High-sensitivity C-reactive protein (hs-CRP).
● The Answer: C (Estimated Glomerular Filtration Rate (eGFR).)
● Distractor Analysis:
○ A is incorrect: The PREVENT equation explicitly removes race from its algorithm to
eliminate historical demographic bias and focus on actual physiology.
○ B & D are incorrect: While useful clinically, they are not the defining new baseline
variables integrated into the core PREVENT mathematical tool.
○ C is correct: PREVENT is the first major tool to mandate kidney health metrics
(eGFR) and metabolic factors as core predictors for ASCVD and Heart Failure.
The Mentor's Analysis: Cardiovascular, kidney, and metabolic systems are not isolated silos;
they operate as a single, interconnected hemodynamic web known as CKM syndrome.
Professional Intuition: You cannot accurately assess the vascular health of the heart without
simultaneously interrogating the filtration pressure of the kidneys. The endothelium is
, contiguous.
Q4: A client formerly diagnosed with "Nonalcoholic Fatty Liver Disease" (NAFLD) is being
re-evaluated under the updated 2025/2026 nomenclature standard. To accurately diagnose the
client with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), the practitioner
MUST definitively identify hepatic steatosis alongside which of the following? A) A history of
chronic alcohol consumption exceeding 210 g/week. B) At least one cardiometabolic risk factor,
such as hypertension, obesity, or type 2 diabetes. C) A diagnostic liver biopsy demonstrating
bridging fibrosis and hepatocyte ballooning. D) Elevated liver transaminases (AST/ALT)
exceeding three times the upper limit of normal.
● The Answer: B (At least one cardiometabolic risk factor, such as hypertension, obesity, or
type 2 diabetes.)
● Distractor Analysis:
○ A is incorrect: Heavy alcohol use reclassifies the patient into the "MetALD" category
or alcohol-related liver disease, removing them from pure MASLD.
○ C & D are incorrect: Biopsy and severe transaminase elevations denote severity
(MASH) but are not the baseline definitional requirements for the overarching
MASLD umbrella.
The Mentor's Analysis: The nomenclature shift from NAFLD to MASLD is not merely semantic;
it is a profound clinical acknowledgment that steatosis is a direct downstream consequence of
systemic metabolic dysfunction. Professional Intuition: Always treat a fatty liver as a
screaming metabolic red flag, inextricably linked to cardiovascular and diabetic risk profiles. It is
a systemic disease, not a localized hepatic anomaly.
Q5: An advanced practice nurse in Texas is utilizing a predictive AI algorithm to assist in
diagnosing a highly complex dermatological lesion. To comply with Texas Senate Bill 1188
(effective Sept 2025), what is the MANDATORY action the practitioner must execute? A) Obtain
written consent from the Texas Medical Board prior to utilizing the software on the clinic network.
B) Disclose the use of the AI diagnostic technology clearly and conspicuously to the patient. C)
Ensure the AI algorithm is hosted on a cloud server physically located in the European Union to
guarantee privacy. D) Anonymize all patient data entirely before the AI processes the diagnostic
image.
● The Answer: B (Disclose the use of the AI diagnostic technology clearly and
conspicuously to the patient.)
● Distractor Analysis:
○ A is incorrect: TMB consent per use is not required, though the practitioner must
review outputs according to standard TMB rules.
○ C is incorrect: SB 1188 strictly prohibits the physical offshoring of Electronic Health
Records (data localization mandate).
○ D is incorrect: While HIPAA privacy is paramount, explicit disclosure of the AI's role
in the care process is the specific, novel legal mandate created by this bill.
The Mentor's Analysis: AI is a powerful decision-support tool, but it does not absorb clinical or
legal liability. The law demands total transparency so patients maintain autonomy over their care
pathways. Professional Intuition: Technology supports the diagnosis, but the practitioner owns
the outcome and the ethical duty to disclose. Never hide the algorithm behind the curtain.
Q6: A hospital network is auditing its internal protocols to ensure strict compliance with the Joint
Commission's National Performance Goal 12 (NPG 12) for 2026. Which action demonstrates
STRICT COMPLIANCE with this new standard? A) Implementing a rigid, hospital-wide ratio of 1
nurse to 5 patients across all acute care units. B) Designating a licensed Nurse Executive (RN)
to oversee continuous, acuity-based staffing assessments and 24/7 RN coverage. C) Replacing
